Impact of molecular residual disease post allografting in myelofibrosis patients

We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F ( n =101), thrombopoietin receptor gene (MPL) ( n =4) or calreticulin (CALR) ( n =31) mutation in peripheral blood on day +1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2017-11, Vol.52 (11), p.1526-1529
Hauptverfasser: Wolschke, C, Badbaran, A, Zabelina, T, Christopeit, M, Ayuk, F, Triviai, I, Zander, A, Alchalby, H, Bacher, U, Fehse, B, Kröger, N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F ( n =101), thrombopoietin receptor gene (MPL) ( n =4) or calreticulin (CALR) ( n =31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50–70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18–34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P
ISSN:0268-3369
1476-5365
DOI:10.1038/bmt.2017.157